Apologies, but no results were found. Perhaps searching will help find a related post.
Certain of the statements made in this corporate blog and elsewhere on the website regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the potential efficacy and use of betrixaban as a Factor Xa inhibitor, of andexanet alfa to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor, and of cerdulatinib as a kinase inhibitor. Risks that contribute to the uncertain nature of the forward-looking statements include: Portola expects to incur losses for the foreseeable future and will need additional funds to finance its operations; its operating results fluctuate significantly; its estimates regarding its ability to initiate and complete its clinical trials and the timing and expense of these trials may not be accurate; enrollment in its clinical trials may be delayed; its clinical trials may not demonstrate the efficacy and safety of its product candidates; its estimates regarding its expenses and capital requirements may not be accurate; regulatory developments in the United States and foreign countries may adversely affect its operations or prospects; it must obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel could adversely affect its operations. These and other risks and uncertainties are described more fully in Portola’s most recent filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q.